-
November 30, 2022
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
-
November 10, 2022
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
-
November 1, 2022
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-
October 26, 2022
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
-
September 30, 2022
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
-
September 22, 2022
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
-
September 6, 2022
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
August 15, 2022
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
August 1, 2022
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
-
July 8, 2022
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022